Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Argos Therapeutics Announces Filing of Its Annual Report on Form 10-K
GlobeNewswire - Mon Apr 07, 3:45PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
Argos Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 3:30PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that the Company will be presenting at the 13 Annual Needham Healthcare Conference on April 8, 2014, at 2:20 p.m. Eastern Time. The conference will be held at The Westin Grand Central Hotel, in New York, NY.
Argos Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that the company has been added to the Russell 2000(R) Index and the Russell 3000(R) Index. The addition is effective as of March 31, 2014.
Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
- AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year -
Argos Therapeutics to Present at 21st Annual Future Leaders in the Biotech Industry Conference
GlobeNewswire - Fri Mar 21, 11:30AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that Jeffrey Abbey, president and chief executive officer, will present at the upcoming 21 Annual Future Leaders in the Biotech Industry conference. Mr. Abbey will provide a review of progress in the pivotal ADAPT Phase 3 clinical trial for AGS-003, Argos's fully personalized immunotherapy currently in development for the treatment of metastatic renal cell carcinoma, and additional updates for the AGS-004 Phase 2 program in HIV. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.
Argos Therapeutics to Present at Regenerative Medicine and Cancer Immunotherapy Meetings
GlobeNewswire - Wed Mar 19, 3:45PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that the company will be presenting at the Second Annual Regen Med Investor Day hosted by the Alliance for Regenerative Medicine on March 26, and the 4 Annual Cancer Immunotherapy: A Long Awaited Reality Conference presented by Maidstone Life Sciences on March 27. Frederick Miesowicz, Ph.D., chief operating officer of Argos, will be presenting on behalf of the company at both events and will be providing an update on progress related to the development of AGS-003, Argos's fully personalized immunotherapy currently in a pivotal phase 3 clinical trial for the treatment of metastatic renal cell carcinoma, and upcoming milestones.
Argos Therapeutics to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
GlobeNewswire - Mon Mar 17, 8:02AM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that Doug Plessinger, vice president of clinical and medical affairs, is scheduled to present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York City. Mr. Plessinger's presentation will include an update on Argos's clinical development program for AGS-003, the company's personalized immunotherapy currently in a pivotal phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.
Argos Therapeutics to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call on Thursday, March 27, 2014
GlobeNewswire - Fri Mar 14, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
Argos Therapeutics Presents New Data From Clinical Research for AGS-004 Patient-Specific Immunotherapy in Treatment of HIV
GlobeNewswire - Tue Mar 04, 3:00PM CST
Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today presented data from clinical studies of AGS-004, the company's patient-specific immunotherapy currently in development for the treatment of HIV infection. Results were presented in two poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Boston.
Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics
Business Wire - Thu Feb 20, 8:24AM CST
Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics ("Argos" or "the Company"
Argos Therapeutics Prices Initial Public Offering
PR Newswire - Fri Feb 07, 5:00AM CST
Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Argos. In addition, the underwriters have an option for a period of 30 days to purchase up to 843,750 additional shares of common stock from Argos at the public offering price, less the underwriting discount. Argos' common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "ARGS" on February 7, 2014.
Argos Therapeutics To Present Progress Update On Adapt Phase 3 Trial With AGS-003 At 2014 Genitourinary Cancers Symposium
PR Newswire - Tue Jan 28, 8:00AM CST
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). The update will be presented in a poster presentation entitled "ADAPT: An Ongoing International Phase III Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment in Advanced Renal Cell Carcinoma (RCC)" on Saturday, February 1, 2014, at 6:45 AM during General Poster Session C at the Genitourinary Cancers Symposium being held in San Francisco.
Sears and Kmart Recall Kenmore Oscillating Fan Heaters Due to Fire and Burn Hazards
PR Newswire - Wed Jan 15, 8:00AM CST
Consumers should stop using this product unless otherwise instructed. It is illegal to resell or attempt to resell a recalled consumer product.
Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
PR Newswire - Wed Nov 20, 8:07AM CST
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that on November 4, 2013, the Company increased the size of its previously announced Series E financing by $17.5 million, bringing the total amount of committed funds from $42.5 million to $60 million.
Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
PR Newswire - Tue Nov 12, 1:00PM CST
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that Jeff Abbey, president and chief executive officer, is scheduled to present at the Elsevier Therapeutic Area Partnerships Meeting on November 19 at the Hyatt Regency Boston.
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
PR Newswire - Mon Nov 11, 8:00AM CST
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, presented an analysis of data from its Phase 2 clinical trial showing that treatment with AGS-003, the company's lead product candidate, in combination with sunitinib, induced memory T cell responses in metastatic renal cell cancer (mRCC) patients that correlated with statistical significance to overall survival (OS). The poster, entitled "Multi-Functional Cytotoxic T Cell Expansion Correlates with Overall Survival after Administration of Autologus Dendritic Cell Immunotherapy in Renal Cell Cancer Patients," was presented on November 9 at the 28th Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland.
JAIDS Study by Argos Therapeutics Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients
GlobeNewswire - Mon Sep 16, 7:07AM CDT
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced the publication of key findings on its dendritic cell-based immunotherapy, AGS-004 in the treatment of HIV-infected patients receiving antiretroviral therapy (ART). The study confirmed that antiviral cytotoxic T-cell immunity can be induced in HIV infected patients without being accompanied by generalized systemic immune activation.
Argos Therapeutics to Present at the Stifel Healthcare Conference 2013
GlobeNewswire - Fri Sep 06, 8:45AM CDT
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, announced today that Jeff Abbey, President and Chief Executive Officer, is scheduled to present at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston.
Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy
GlobeNewswire - Tue Aug 27, 7:00AM CDT
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that it has secured $42.5 million in a Series E financing. The funds will be used for the company's ongoing, fully resourced ADAPT pivotal Phase 3 clinical study of AGS-003 for metastatic renal cell carcinoma (mRCC).